New means to monitor the effect of glucocorticoid therapy in children

World Journal of Gastroenterology

Volumn 16, Issue 9, 2010, Pages 1104-1109

  Rintamäki, Hanne ^a   Salo, Harri M ^b   Vaarala, Outi ^b   Kolho, Kaija Leena ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Children; FOXP3; Glucocorticoid induced tumor necrosis factor receptor; Inflammatory bowel disease

Indexed keywords

AZATHIOPRINE; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 5; MESALAZINE; PREDNISOLONE; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CELL ASSAY; CHILD; CLINICAL ARTICLE; COLITIS; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOKINE RELEASE; DRUG EFFECT; DRUG MONITORING; ENTERITIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; SIGNAL TRANSDUCTION; TARGET CELL; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 77949469127     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i9.1104     Document Type: Article

References (27)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048
2. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-362
3. Tung J, Loftus EV Jr, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ 3rd, Harmsen WS, Sandborn WJ, Faubion WA Jr. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006; 12: 1093-1100
4. Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A, Otley A, Evans J, Pfefferkorn M, Rosh J, Rothbaum R, Kugathasan S, Mezoff A, Wyllie R, Tolia V, delRosario JF, Moyer MS, Oliva-Hemker M, Leleiko N. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006; 4: 1118-1123
5. Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut 2003; 52: 1432-1434
6. Turunen P, Kolho KL, Auvinen A, Iltanen S, Huhtala H, Ashorn M. Incidence of inflammatory bowel disease in Finnish children, 1987-2003. Inflamm Bowel Dis 2006; 12: 677-683
7. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-1640
8. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 2004; 1024: 124-137
9. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004; 500: 51-62
10. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723
11. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27: 413-426
12. Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyteendothelial interactions by glucocorticoids. Ann N Y Acad Sci 2002; 966: 108-118
13. Vihinen MK, Kolho KL, Ashorn M, Verkasalo M, Raivio T. Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol 2008; 159: 693-698
14. Vihinen MK, Raivio T, Verkasalo M, Jänne OA, Kolho KL. Circulating glucocorticoid bioactivity during peroral glucocorticoid treatment in children and adolescents with inflammatory bowel disease. J Clin Gastroenterol 2008; 42: 1017-1024
15. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6; discussion 16-19
16. Halminen M, Klemetti P, Vaarala O, Hurme M, Ilonen J. Interferon-gamma production in antigen specific T cell response: quantitation of specific mRNA and secreted protein. Scand J Immunol 1997; 46: 388-392
17. Honkanen J, Skarsvik S, Knip M, Vaarala O. Poor in vitro induction of FOXP3 and ICOS in type 1 cytokine environment activated T-cells from children with type 1 diabetes. Diabetes Metab Res Rev 2008; 24: 635-641
18. Nocentini G, Giunchi L, Ronchetti S, Krausz LT, Bartoli A, Moraca R, Migliorati G, Riccardi C. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci USA 1997; 94: 6216-6221
19. Yi H, Zhen Y, Jiang L, Zheng J, Zhao Y. The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells. Cell Mol Immunol 2006; 3: 189-195
20. Kaplan HP, Portnoy B, Binder HJ, Amatruda T, Spiro H. A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. Gastroenterology 1975; 69: 91-95
21. Powell-Tuck J, Buckell NA, Lennard-Jones JE. A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis. Scand J Gastroenterol 1977; 12: 971-975
22. Leonhardt SA, Edwards DP. Mechanism of action of progesterone antagonists. Exp Biol Med (Maywood) 2002; 227: 969-980
23. Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Rückert B, Mantel PY, Menz G, Akdis CA, Blaser K, Schmidt-Weber CB. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114: 1425-1433
24. Zhang Q, Qian FH, Liu H, Zhou LF, Huang M, Zhang XL, Yin KS. Expression of surface markers on peripheral CD4+CD25high T cells in patients with atopic asthma: role of inhaled corticosteroid. Chin Med J (Engl) 2008; 121: 205-212
25. Malmhäll C, Bossios A, Pullerits T, Lötvall J. Effects of pollen and nasal glucocorticoid on FOXP3+, GATA-3+ and T-bet+ cells in allergic rhinitis. Allergy 2007; 62: 1007-1013
26. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O'Shea JJ, Chrousos GP, Bornstein SR. Gene pro-filing reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002; 16: 61-71
27. Turner D, Walsh CM, Benchimol EI, Mann EH, Thomas KE, Chow C, McLernon RA, Walters TD, Swales J, Steinhart AH, Griffiths AM. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008; 57: 331-338